Isolation, characterization, and expression of stromelysin-1 in primary tumors of dogs

American Journal of Veterinary Research

Volumn 66, Issue 9, 2005, Pages 1526-1535

  Sorensen, Kara C ^a,b   Newman, Rebecca G ^a,c   Kitchell, Barbara E ^a,c   Schaeffer, David J ^a   Siegel, Arthur M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b LAC+USC Medical Center   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MATRIX METALLOPROTEINASE; STROMELYSIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA SEQUENCE; DOG DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN ISOLATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DOG DISEASES; DOGS; GENE COMPONENTS; GENE EXPRESSION; MATRIX METALLOPROTEINASE 3; MOLECULAR SEQUENCE DATA; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

ANIMALIA; CANIS FAMILIARIS;

EID: 27744558163     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1526     Document Type: Article

References (60)

1. Nikkola J, Vihinen P, Vlaykova T, et al. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002; 97:432-438.
2. Murphy G, Cockett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991;277:277-279.
3. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31:34-45.
4. Matrisian LM, Bowden GT, Krieg P, et al. The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. Proc Natl Acad Sci U S A 1986;83:9413-9417.
5. Arai Y, Kubo T, Kobayashi K, et al. Adenovirus vector-mediated gene transduction to chondrocytes: in vitro evaluation of therapeutic efficacy of transforming growth factor-beta 1 and heat shock protein 70 gene transduction. J Rheumatol 1997;24:1787-1795.
6. Schmitz JP, Dean DD, Schwartz Z, et al. Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein: stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles. J Cell Biochem 1996;61:375-391.
7. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996;15:869-875.
8. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989;84:1657-1662.
9. Schatz F, Papp C, Toth-Pal E, et al. Ovarian steroid-modulated stromelysin-1 expression in human endometrial stromal and decidual cells. J Clin Endocrinol Metab 1994;78:1467-1472.
10. Bryant-Greenwood GD, Yamamoto SY. Control of peripartal collagenolysis in the human chorion-decidua. Am J Obstet Gynecol 1995;172:63-70.
11. Madlener M. Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds. Arch Dermatol Res 1998;290(suppl):S24-S29.
12. Leppert D, Hauser SL, Lishiyama JL, et al. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995;9:1473-1481.
13. Nelson A, Fingleton B, Rothenberg M, et al. The matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
14. De Angelis T, Noe A, Chaterjee M, et al. Stromelysin-1 activation correlates with invasiveness in squamous cell carcinoma. J Invest Dermatol 2002;118:759-766.
15. Giambernardi TA, Grant GM, Taylor GP et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998;16:483-496.
16. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix me-talloproteinases in human normal livers and primary liver tumors. Hepatology 1996;23:1341-1344.
17. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;52:1302-1312.
18. Kolb SA, Lahrtz F, Paul R, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 1998;84:143-150.
19. D'Souza CA, Mak B, Moscarello MA. The up-regulation of stromelysin-1 (MMP-3) in a spontaneously demyelinating transgenic mouse precedes onset of disease. J Biol Chem 2002;277:13589-13596.
20. Carrell TWG, Burnand KG, Wells GMA, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are over expressed in the wall of abdominal aortic aneurysms. Circulation 2001;105:477-482.
21. Hatamochi A, Kuroda K, Shinkai H, et al. Regulation of matrix metalloproteinase (MMP) expression in cutis laxa fibroblasts: upregulation of MMP-1, MMP-3 and MMP-9 genes but not of the MMP-2 gene. Br J Dermatol 1998;138:757-762.
22. Murawaki Y, Ikuta Y, Okamoto K, et al. Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease. J Hepatol 1999;31:474-478.
23. Panula HE, Lohmander LS, Ronkko S, et al. Elevated levels of synovial fluid PLA2, stromelysin (MMP-3) and TIMP in early osteoarthrosis after tibial valgus osteotomy in young beagle dogs. Acta Orthop Scand 1998;69:152-158.
24. Fernandes JC, Martel-Pelletier J, Otterness IG, et al. Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995;38:1290-1303.
25. Posthumus MD, Limburg PC, Westra J, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 1999;38:1081-1087.
26. Tomita T, Nakase T, Kaneko M, et al. Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinase in rheumatoid arthritis. Arthritis Rheum 2002;46:373-378.
27. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994;47:113-116.
28. Sharma R, Suzuki K, Nagase H, et al. Matrix metalloproteinase (stromelysin-1) increases the albumin permeability of isolated rat glomeruli. J Lab Clin Med 1996;128:297-303.
29. Pikul S, McDow Dunham KL, Almstead NG, et al. Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem 1998;41:3568-3571.
30. Pascual-Le Tallec L, Korwin-Zmijowska C, Adolphe M. Effects of simulated solar radiation on type I and type III collagens, collagenase (MMP-1) and stromelysin (MMP-3) gene expression in human dermal fibroblasts cultured in collagen gels. J Photochem Photobiol B 1998;42:226-232.
31. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998;290(suppl):S47-S54.
32. Hughes PM, Wells GM, Clements JM, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121:481-494.
33. Bannikov GA, Karelina TV, Collier IE, et al. Substrate binding of gelatinase B induced its enzymatic activity in the presence of intact propeptide. J Biol Chem 2002;277:16022-16027.
34. Unemori EN, Bair MJ, Bauer EA, et al. Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-gamma. J Biol Chem 1991;266:23477-23482.
35. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
36. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
37. Oliver LG, Smith JL, Toivio-Kinnucan BB, et al. Biologic characterization of canine melanoma cell lines. Am J Vet Res 1987; 48:1642-1648.
38. Kasza L. Establishment and characterization of canine thyroid adenocarcinoma and canine melanoma cell lines. Am J Vet Res 1964;25:1178-1185.
39. National Research Council. Institutional policies and responsibilities. In: Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996;8-20.
40. Chirgwin JM, Przybyla AE, MacDonald RJ, et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-5299.
41. Houts G, Miyagi M, Ellis C, et al. Reverse transcriptase from avian myeloblastosis virus. J Virol 1979;29:517-522.
42. Griffaies R, Andre PM, Thibon M. K-tuple frequency in the human genome and polymerase chain reaction. Nucleic Acids Res 1991;19:3887-3991.
43. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402.
44. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
45. Smith TL, Putman JE, Gehan EA. A computer program for estimating survival functions from the life table. Comput Programs Biomed 1970;1:58-64.
46. Lee ET. Statistical methods for survival data analysis. Belmont, Calif: Lifetime Learning Publications, 1980;430-434.
47. FDA. Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Rockville, Md: FDA, 1992.
48. Hald A. Statistical theory with engineering applications. New York: John Wiley & Sons, 1952;221-239.
49. SYSTAT 10.2 statistics I & II. Richmond, Calif: SYSTAT Software Inc, 2002.
50. Springman EB, Angleton EL, Birkedal-Hansen H, et al. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87:364-368.
51. Murphy GJ, Murphy G, Reynolds JJ. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1991;289:4-7.
52. Brancho MA, Moya A, Barrio E. Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity. J Gen Virol 1998;79:2921-2928.
53. Sang QA, Douglas DA. Computational sequence analysis of matrix metalloproteinases. J Protein Chem 1996;15:137-160.
54. Stryer L. Chapter 2. In: Biochemistry. 4th ed. New York: WH Freeman & Co, 1995;21-22.
55. Sorensen KC, Kitchell BE, Siegel AM, et al. Isolation, characterization, and expression of feline stromelysin-1 in naturally developing tumors in cats. Am J Vet Res 2004;65:213-219.
56. Aimes RT, French DL, Quigley JP. Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation. Biochem J 1994;300:729-736.
57. Witte J, Goretzki PE, Dieken J, et al. Importance of lymph node metastases in follicular thyroid cancer. World J Surg 2002;26:1017-1022.
58. Noguchi M. Does regional treatment improve the survival in patients with operable breast cancer? Breast Cancer Res Treat 2002;76:269-282.
59. Shima I, Saspuri Y, Kusukawa J, et al. Production of matrix me-talloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathological study. Cancer 1992;70:2747-2753.
60. Skiles JW, Gonnella NC, Jeng AV. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004;11:2911-2977.